ClinicalTrials.gg
CompletedNCT06884085Updated Dec 1, 2025

A Study to Compare to PK Characteristics and Safety Profiles Between AD-227 and Co-administration of AD-227A and AD-227B

A Phase 1 interventional study of Co-administration of AD-227A and AD-227B and Administration of AD-227 in Primary Hypertension, sponsored by Addpharma Inc.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 10 studies in Essential Hypertension by Yuhan Corporation — 2 open to participants now, 4 under way, 2 of them phase 3. Essential Hypertension · Yuhan Corporation.

Started
2025
the only one that year
Phase 1
Only one
of the 10
Registered
10th of 10
by date

Among the 10 studies in Essential Hypertension by Yuhan Corporation, this one is the only one that started in 2025, is the only one in phase 1, and was the 10th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

2 of the 10 studies in Essential Hypertension by Yuhan Corporation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Essential Hypertension by Yuhan Corporation, or all of them as a file.
02

Study summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.

03

Conditions studied

  • Primary Hypertension
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight equal to or greater than 50kg (Female 45kg) and (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
  • The Age equal to or greater than 19 in healthy volunteers at the time of screening visit

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study with an drug within the 6 months from scheduled first administration
  • Other exclusions applied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Sequence A (RT)

    Period 1: Reference (Co-administration of AD-227A and AD-227B), Period 2: Test (AD-227)

    Drug: Co-administration of AD-227A and AD-227B · Drug: Administration of AD-227

  • Experimental
    Sequene B (TR)

    Period 1: Test (AD-227), Period 2: Reference (Co-administration of AD-227A and AD-227B)

    Drug: Co-administration of AD-227A and AD-227B · Drug: Administration of AD-227

Interventions

  • DrugCo-administration of AD-227A and AD-227B

    Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral

  • DrugAdministration of AD-227

    Administration of AD-227 1Tab., Per Oral

06

What researchers measure

Primary outcomes

  1. Maximum concentration of drug in plasma (Cmax)

    Cmax of AD-227

    Time frame: pre-dose (0hour) to 72hours

  2. Area under the plasma concentration-time curve during dosing interval (AUCt)

    AUCt of AD-227

    Time frame: pre-dose (0hour) to 72hours

07

Study locations

1 site
  • Central Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Aug 2025, 1 month.

Of 18 phase 1 interventional studies under Essential Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2025
First posted
Mar 19, 2025
StartActual
Jul 12, 2025
Primary completionActual
Aug 13, 2025
CompletionActual
Aug 13, 2025
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06884085
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Jul 12, 2025
Primary completion
Aug 13, 2025
Completion
Aug 13, 2025
Last update
Dec 1, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion